Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
PARIS, May 10, 2017 -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the specific route of administration for Livatag®, which is currently in a phase III clinical trial (ReLive) for the second-line treatment of hepatocellular carcinoma (primary liver cancer).
Livatag® (doxorubicin Transdrug™) is based on an innovative technology allowing the formulation of doxorubicin (a chemotherapeutic agent) within nanoparticles composed of polyalkylcyanoacrylate, cyclodextrin, and poloxamer. This nanoparticle formulation provides new and promising properties, including overcoming the mechanisms of chemoresistance developed by tumor cells that affect the efficacy of chemotherapy agents.
“The United States represents a significant target market for Livatag®. This new U.S. patent significantly strengthens our Livatag® intellectual property portfolio, and enhances the value of this late-stage product candidate. We look forward to the availability of data from our ReLive trial in mid-2017,” said Judith Greciet, CEO of Onxeo.
The new patent provides protection of the associated claims in the U.S. until 2032, and is in addition to the previously issued patents for the same patent family in other major territories, such as Europe and Japan. An additional patent family has also been filed based on a specific composition of Livatag® nanoparticles that, if granted, would extend the patent protection of Livatag® to 2036.
About Onxeo
Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry.
Onxeo’s objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers.
Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications.
The Company is headquartered in Paris, France with offices in Copenhagen and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596).
Learn more by visiting www.onxeo.com
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2016 Reference Document filed with the AMF on April 24, 2017, which is available on the AMF website (www.amf-france.org) or on the company’s website (www.onxeo.com).
Onxeo Valerie Leroy, Investor Relations [email protected] +33 1 45 58 76 00 Media Relations Caroline Carmagnol / Simon Derbanne Alize RP [email protected] +33 6 64 18 99 59 / +33 6 38 16 26 41 Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh NewCap [email protected] +33 1 44 71 94 92 Investor Relations US Brian Ritchie LifeSci Advisors [email protected] +1 212 915 2578
